INMED PHARMACEUTICALS INC. Financing Cash Flow
INMED PHARMACEUTICALS INC. (INM) reported Financing Cash Flow of $94.50 thousand for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$1.00, a 100.00% decline year-over-year.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $231.68K, a 92.07% decline year-over-year.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$137.18K, a 116.37% decline year-over-year.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) financing activities for fiscal 2023 was $10.68M, a 29.13% decline from fiscal 2022.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) financing activities for fiscal 2022 was $15.07M, a 38.84% increase from fiscal 2021.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) financing activities for fiscal 2021 was $10.85M.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) financing activities for fiscal 2020 was -$30.99K.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.00 derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $231.67K derived: sum of 2 quarters · filed 2026-09-09 | $231.67K derived: sum of 3 quarters · filed 2026-09-09 | $94.50K S-4/A · filed 2026-09-09 |
| 2026-03-31 | $231.68K derived: S-4 9 month − 10-Q 6 month · filed 2026-07-02 | $231.68K derived: sum of 2 quarters · filed 2026-07-02 | $94.50K S-4 · filed 2026-07-02 | $8.27M derived: sum of 4 quarters · filed 2026-09-09 |
| 2025-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | -$137.18K 10-Q · filed 2026-02-11 | $8.04M derived: sum of 3 quarters · filed 2026-09-09 | $10.96M derived: sum of 4 quarters · filed 2026-09-09 |
| 2025-09-30 | -$137.18K 10-Q · filed 2025-11-06 | $8.04M derived: sum of 2 quarters · filed 2026-09-09 | $10.96M derived: sum of 3 quarters · filed 2026-09-09 | $11.30M derived: sum of 4 quarters · filed 2026-09-09 |
| 2025-06-30 | $8.17M derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $11.09M derived: sum of 2 quarters · filed 2026-09-09 | $11.43M derived: sum of 3 quarters · filed 2026-09-09 | $12.27M S-4/A · filed 2026-09-09 |
| 2025-03-31 | $2.92M derived: S-4 9 month − 10-Q 6 month · filed 2026-07-02 | $3.26M derived: sum of 2 quarters · filed 2026-07-02 | $4.10M S-4 · filed 2026-07-02 | $4.10M derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-12-31 | $338.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | $1.18M 10-Q · filed 2026-02-11 | $1.18M derived: sum of 3 quarters · filed 2026-07-02 | $1.18M derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-09-30 | $838.24K 10-Q · filed 2025-11-06 | $838.41K derived: sum of 2 quarters · filed 2026-07-02 | $838.41K derived: sum of 3 quarters · filed 2026-07-02 | |
| 2024-06-30 | $176.00 derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | $176.00 derived: sum of 2 quarters · filed 2026-07-02 | $4.65M S-4 · filed 2026-07-02 | |
| 2024-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $4.65M 10-Q · filed 2025-05-12 | ||
| 2023-12-31 | $4.65M 10-Q · filed 2025-02-12 | |||
| 2023-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | -$63.70K derived: sum of 2 quarters · filed 2024-09-30 | $5.25M derived: sum of 3 quarters · filed 2024-09-30 | $10.68M 10-K · filed 2024-09-30 |
| 2023-03-31 | -$63.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | $5.25M derived: sum of 2 quarters · filed 2024-02-13 | $10.68M 10-Q · filed 2023-05-15 | $15.73M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-12-31 | $5.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | $10.74M 10-Q · filed 2024-02-13 | $15.80M derived: sum of 3 quarters · filed 2024-02-13 | $15.77M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | $5.43M 10-Q · filed 2023-11-14 | $10.48M derived: sum of 2 quarters · filed 2023-11-14 | $10.45M derived: sum of 3 quarters · filed 2023-11-14 | $9.61M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $5.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-29 | $5.02M derived: sum of 2 quarters · filed 2023-09-29 | $4.19M derived: sum of 3 quarters · filed 2023-09-29 | $15.07M 10-K · filed 2023-09-29 |
| 2022-03-31 | -$29.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | -$865.46K derived: sum of 2 quarters · filed 2023-05-15 | $10.02M 10-Q · filed 2023-05-15 | $9.94M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$836.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-17 | $10.05M 10-Q · filed 2023-02-17 | $9.97M derived: sum of 3 quarters · filed 2023-02-17 | $14.01M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-09-30 | $10.88M 10-Q · filed 2022-11-14 | $10.80M derived: sum of 2 quarters · filed 2022-11-14 | $14.85M derived: sum of 3 quarters · filed 2022-11-14 | $21.80M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$83.18K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | $3.96M derived: sum of 2 quarters · filed 2022-09-23 | $10.92M derived: sum of 3 quarters · filed 2022-09-23 | $10.85M 10-K · filed 2022-09-23 |
| 2021-03-31 | $4.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-13 | $11.00M derived: sum of 2 quarters · filed 2022-05-13 | $10.94M 10-Q · filed 2022-05-13 | |
| 2020-12-31 | $6.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | $6.89M 10-Q · filed 2022-02-14 | ||
| 2020-09-30 | -$64.65K 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | -$30.99K 10-K · filed 2021-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |